Pacific Biosciences upgraded to Neutral from Underweight at JPMorgan JPMorgan upgraded Pacific Biosciences to Neutral citing valuation and stronger system placements following the company's Q1 results. The firm has a $7 price target for shares.
News For PACB From The Last 14 Days
Check below for free stories on PACB the last two weeks.
Pacific Biosciences milestone payment shows Roche commitment, says Maxim Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.